Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active psoriatic arthritis: Data from the GOLMePsA clinical trial

Abstract Objectives To describe the prevalence and extent of whole body (WB)-MRI detected joint disease features and their response to therapy in patients with early, active PsA. Methods Newly diagnosed PsA patients (treatment-naïve), recruited in GOLMePsA randomized trial (methotrexate plus golimumab and steroids, GOLMTX vs methotrexate plus steroids, PBOMTX), underwent a multi-joint MRI protocol (baseline; week 24 [primary outcome] and week 36). The validated WIPE (peripheral joints and entheses); HIMRISS, KIMRISS (hip and knee); HEMRIS (heel); and CANDEN and SPARCC (sacroiliac joints (SIJs), spine) scores were recorded. Exploratory estimates of difference or ratios (with confidence intervals - CI; 75-95%) between groups at weeks 24 and 36, were obtained using multiple binary logistic or quantile (median) regression. Results Overall, 93 paired scans from 31 participants (median symptom duration 10.5 months; IQR 4.2-18.3; absolute range 1.8-197.7; 68% polyarticular) were included. Baseline scores showed widespread low intensity inflammation in peripheral tissues (median MRI-WIPE score: 37 – CI 19.0-55.0). SIJs and spine inflammation (SPARCC score ≥2) was seen in 25.8% (10/31) and 32.3% (10/31), respectively. Participants achieved median MRI-WIPE delta (the difference between time-points) of -10 at week 24 and -7 at week 36 in the GOLMTX and -6 and -9 in PBOMTX arms respectively. No differences between treatment groups were observed. Conclusions In this exploratory analysis, WB-MRI identified widespread although low intensity inflammation in peripheral joints and enthesis with improvements seen at 24 and 36 weeks and no meaningful differences between treatment arms. Axial abnormalities were seen in one third of patients at baseline. Clinical Trial registration Clinicaltrials.gov; NCT04108468

Authors

Institutions

Publication Details

Journal
Lara D. Veeken
Published
2026-06-16
DOI
https://doi.org/10.1093/rheumatology/keag308
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active psoriatic arthritis: Data from the GOLMePsA clinical trial

E. Hensor, Ai Lyn Tan, Philip Helliwell, Helena Marzo‐Ortega et al.
Lara D. Veeken
Spondyloarthritis Studies and Treatments
article

Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active psoriatic arthritis: Data from the GOLMePsA clinical trial

E. Hensor, Ai Lyn Tan, Philip Helliwell, Helena Marzo‐Ortega, Iris Eshed, Walter P. Maksymowych, Dennis McGonagle, Mikkel Østergaard, Gabriele De Marco
article en

Abstract

Abstract Objectives To describe the prevalence and extent of whole body (WB)-MRI detected joint disease features and their response to therapy in patients with early, active PsA. Methods Newly diagnosed PsA patients (treatment-naïve), recruited in GOLMePsA randomized trial (methotrexate plus golimumab and steroids, GOLMTX vs methotrexate plus steroids, PBOMTX), underwent a multi-joint MRI protocol (baseline; week 24 [primary outcome] and week 36). The validated WIPE (peripheral joints and entheses); HIMRISS, KIMRISS (hip and knee); HEMRIS (heel); and CANDEN and SPARCC (sacroiliac joints (SIJs), spine) scores were recorded. Exploratory estimates of difference or ratios (with confidence intervals - CI; 75-95%) between groups at weeks 24 and 36, were obtained using multiple binary logistic or quantile (median) regression. Results Overall, 93 paired scans from 31 participants (median symptom duration 10.5 months; IQR 4.2-18.3; absolute range 1.8-197.7; 68% polyarticular) were included. Baseline scores showed widespread low intensity inflammation in peripheral tissues (median MRI-WIPE score: 37 – CI 19.0-55.0). SIJs and spine inflammation (SPARCC score ≥2) was seen in 25.8% (10/31) and 32.3% (10/31), respectively. Participants achieved median MRI-WIPE delta (the difference between time-points) of -10 at week 24 and -7 at week 36 in the GOLMTX and -6 and -9 in PBOMTX arms respectively. No differences between treatment groups were observed. Conclusions In this exploratory analysis, WB-MRI identified widespread although low intensity inflammation in peripheral joints and enthesis with improvements seen at 24 and 36 weeks and no meaningful differences between treatment arms. Axial abnormalities were seen in one third of patients at baseline. Clinical Trial registration Clinicaltrials.gov; NCT04108468

Lara D. Veeken
University of Leeds (GB), University of Alberta (CA), Tel Aviv University (IL), Leeds Teaching Hospitals NHS Trust (GB), Sheba Medical Center (IL), Glostrup Hospital (DK), Copenhagen University Hospital (DK), NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
Good health and well-being
Openalex Percentile: Top 5%
Spondyloarthritis Studies and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.